Kenox Pharmaceuticals Announces Strategic Collaboration with Lactiga to Advance Mucosal-Targeted Immunotherapy
Kenox Pharmaceuticals Inc. and Lactiga US, Inc. are pleased to announce a strategic collaboration to advance the development ...
Business Wire1mon
Lactiga Secures Multi-Year, Multi-Million Dollar Grant from NIH’s National Institute of Allergy and Infectious Diseases to Advance Groundbreaking, Mucosal-Targeted Secretory ...
This funding will accelerate the advancement of Lactiga’s lead asset, LCTG-001—the first-ever secretory IgA (sIgA) mucosally-targeted replacement therapy for patients with compromised immune ...
Pharmabiz7d
Kenox Pharma partners with Lactiga for development of novel mucosal-targeted Secretory IgA therapies for immunodeficient patients
Kenox Pharma partners with Lactiga for development of novel mucosal-targeted Secretory IgA therapies for immunodeficient patients: Princeton, New Jersey Wednesday, March 12, 2025, ...
Medscape1mon
Breast Milk: Proactive Immunomodulation and Mucosal Protection Against Viruses and Other Pathogens
Reflecting maternal environmental exposition and in virtue of its multiple mechanism of action, secretory IgA in milk exerts a decisive role in direct and cross-protection against a variety of ...
BMJ10mon
Effects of 12 months of exercise training on salivary secretory IgA levels in elderly subjects
Upper respiratory tract infection (URTI) is a common illness. Recent studies have shown that suppression of secretory immunoglobulin A (SIgA) is associated with increased incidence of URTI. Objective: ...